Of note, in-vivo chemokine receptor levels seem to be uniformly expressed, as no relevant uptake differences in the primary and metastases (with the exception of lung metastases) were observed, indicating that CXCR4-directed RLT would then exert anti-tumor effects in all lesions attributable to the underlying disease. The gene discussed is CXCR4; the disease is neoplasm.